Devices and methods for treating a mammalian eye

• US 20050244462A1
• Filed: 04/30/2004
• Published: 11/03/2005
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Farooq, Sidiq
• Application Number:
  US10/836,908
• Publication Number:
  US 20050244462A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts

Abstract

Devices and methods for delivering a therapeutically active ocular implant into an eye are provided. Such a device generally includes a hollow sleeve having an open proximal end, a distal end, a substantially uniform inner diameter and a substantially uniform outer diameter extending between the proximal end and the open distal end. In addition, the device includes a plunger element having an angled configuration and sized to be slidably received within the sleeve for urging an implant from the distal end of the sleeve and into an eye. Systems for performing ocular research are provided which include a plurality of such hollow sleeves cut from a single flouroplastic tube, and a plurality of plunger elements cut from a single wire. The devices, systems and methods are especially useful for facilitating implantation of relatively fragile, for example brittle, ocular implants in an intact condition.

Claims

1. A method for treating an eye, the method comprising the steps of:

providing a device comprising a hollow sleeve having an open proximal end, a distal end, a substantially uniform inner diameter and a substantially uniform outer diameter extending between the proximal end and the distal end, the hollow sleeve terminating at the proximal end;

placing a substantially bioerodible implant including a therapeutic component and sized for placement in an eye, in the hollow sleeve;

passing the distal end of the hollow sleeve through a surface of an eye;

introducing the implant into the eye at a location within the eye by passing the implant out of the distal end of the hollow sleeve; and

withdrawing the hollow sleeve from the eye.

2. The method of claim 1 wherein the step of introducing the implant includes advancing a plunger element through the hollow sleeve in a distal direction in order to urge the implant out of the distal end of the hollow sleeve.

3. The method of claim 1 wherein the eye is a mammalian eye.

4. The method of claim 1 wherein the eye is a non-human animal eye.

5. The method of claim 1 wherein the eye is an equine eye.

6. The method of claim 1 wherein the eye is a human eye.

7. The method of claim 1 wherein the step of introducing comprises introducing the implant into an anterior chamber of the eye.

8. The method of claim 1 wherein the step of introducing comprises introducing the implant into a posterior chamber of the eye.

9. The method of claim 1 wherein the step of introducing comprises introducing the implant into a structure of the eye selected from the group consisting of the retina, the vitreous, the cornea, and the scleral of the eye.

10. The method of claim 1 wherein the step of introducing comprises introducing the implant into a structure of the eye selected from the group consisting of the meningeal space, the optic nerve, and the intraoptic nerve.

11. The method of claim 1 wherein the therapeutic component comprises an anti-inflammatory agent.

12. The method of claim 1 wherein the therapeutic component comprises a steroid component.

13. The method of claim 1 wherein the therapeutic component comprises a steroid component selected from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, and mixtures thereof.

14. The method of claim 1 wherein the therapeutic component comprises dexamethasone.

15. The method of claim 1 wherein the implant further includes a polymeric component.

16. The method of claim 11 wherein the polymeric component is selected from the group of polymeric components consisting of lactic acid polymers, glycolic acid polymers, copolymers of lactic acid and glycolic acid, and combinations thereof.

17. The method of claim 1 effective in treating an inflammation-mediated condition of the eye.

18. The method of claim 17 wherein the inflamation mediated condition of the eye is selected from the group consisting of uveitis, macular edema, acute macular degeneration, retinal detachment, ocular tumors, fungal infections, viral infections, multifocal choroiditis, diabetic uveitis, proliferative vitreoretinopathy, sympathetic ophthalmia, Vogt Koyanagi Harada syndrome, histoplasmosis, uveal diffusion, and combinations thereof.

19. The method of claim 1 wherein the implant comprises a generally cylindrically shaped implant configured to fit within the hollow sleeve.

20. The method of claim 19 wherein the inner diameter of the hollow sleeve is greater than an outer diameter of the implant.

21. The method of claim 1 wherein the hollow sleeve is structured to accommodate the implant in a substantially frictionless manner in order to maintain the implant substantially intact while the implant passes through the hollow sleeve and into the eye.

22. The method of claim 1 wherein the hollow sleeve comprises a fluoroplastic material.

23. The method of claim 1 wherein the hollow sleeve includes a material selected from the group consisting of polytetrafluoroethylene, polyperfluoroalkoxyl, ethylene propylene, polyfluorinated ethylene propylene, and combinations thereof.

24. A method of treating an inflammation-mediated condition of an eye comprising the steps of:

providing a device including a hollow sleeve having a distal end;

placing an implant sized for placement in an eye, in the hollow sleeve, the implant being substantially non-flexible and including a therapeutic component and a polymeric component;

passing the distal end of the hollow sleeve through a surface of the eye and into the eye;

introducing the implant into a vitreous of the eye by passing the implant out of the distal end of the hollow sleeve; and

withdrawing the hollow sleeve from the eye.

25. The method of claim 24 wherein the step of introducing the implant includes advancing a plunger element through the hollow sleeve in a distal direction in order to urge the implant out of the distal end of the sleeve and into the vitreous.

26. The method of claim 24 wherein the therapeutic component comprises a steroid component.

27. The method of claim 26 wherein the steroid component is selected from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone and combinations thereof.

28. The method of claim 26 wherein the steroid component comprises dexamethasone.

29. The method of claim 24 wherein the polymeric component is selected from the group consisting of lactic acid polymers, glycolic acid polymers, copolymers of lactic acid and glycolic acid, and combinations thereof.

30. The method of claim 24 wherein the implant is effective in treating an inflamation mediated condition of the eye selected from the group consisting of uveitis, macular edema, acute macular degeneration, retinal detachment, ocular tumors, fungal infections, viral infections, multifocal choroiditis, diabetic uveitis, proliferative vitreoretinopathy, sympathetic ophthalmia, Vogt Koyanagi Harada syndrome, histoplasmosis, uveal diffusion, and combinations thereof.

31. The method of claim 24 wherein the hollow sleeve comprises a fluoroplastic material.

32. An ocular research system comprising:

a plurality of hollow sleeves, wherein each sleeve is substantially identical to each other sleeve, is sized to be inserted into a vitreous of an eye, and includes a proximal end, a distal end, a substantially uniform inner diameter and a substantially uniform outer diameter extending between the proximal end and the distal end.

33. The system of claim 32 wherein the plurality of hollow sleeves are produced by cutting a substantially uniform tube at approximately equally spaced apart intervals.

34. The system of claim 32 further comprising a plurality of plunger elements, each plunger element being structured to be slidably received within one of the hollow sleeves.

35. The system of claim 32 further comprising a plurality of ocular implants, each ocular implant including a therapeutic component and a matrix component and being sized to be slidably received within one of the hollow sleeves.

36. The system of claim 32 wherein each sleeve is sized to be inserted into a vitreous of a rabbit eye.

37. The system of claim 32 wherein each of the hollow sleeves includes a beveled tip on the distal end of the hollow sleeve.

38. A device for delivering an ocular implant into an eye, the device consisting essentially of:

a hollow sleeve including an open proximal end, a distal end, a beveled tip distal to the distal end, a substantially uniform inner diameter and a substantially uniform outer diameter extending between the proximal end and the distal end, the device terminating at and not extending beyond the proximal end, and sized to receive an therapeutic implant; and

a plunger element structured to be slidably received within the hollow sleeve;

the device being structured to be directly manually manipulable when used to introduce a biodegradable implant into a vitreous of an eye.